UnitedHealth Group has taken a significant step toward addressing public concerns about its business practices by announcing the findings of an independent audit carried out by two consultancy firms. This initiative is part of a broader effort to rebuild trust in the health insurance sector, amid growing scrutiny over the practices of private insurers. The audit highlights the company’s commitment to transparency and accountability, embarking on 23 ongoing action plans intended to implement recommended improvements across three key areas of its operations.
The company indicated that approximately 65% of these initiatives are expected to be completed by the end of 2025, with a commitment to achieve full implementation by the end of March next year. This proactive approach follows a particularly challenging period for UnitedHealth Group, which has faced significant backlash over its business policies and is currently under investigation by the Department of Justice for its Medicare billing practices.
The new audit comes shortly after the appointment of CEO Steve Hemsley, who took over in May following the unexpected departure of Andrew Witty. In a statement released alongside the audit results, Hemsley emphasized the company’s dedication to transparency, asserting that every stakeholder deserves to understand UnitedHealth’s operational approach. He acknowledged the substantial impact the company has on patients and healthcare providers, reiterating a commitment to high standards in its practices.
FTI Consulting and The Analysis Group were tasked with analyzing various aspects of UnitedHealthcare’s operations, particularly focusing on the company’s Medicare Advantage programs and the efficiency of its pharmacy benefit manager, Optum Rx. The analysis of Optum Rx aimed to ensure that discounts negotiated with drug manufacturers are accurately collected and distributed to clients. While the firms found much of UnitedHealthcare’s policies and practices to be robust and industry-leading, they also identified areas for enhancement.
The Analysis Group noted that Optum Rx has established a comprehensive framework for managing manufacturer discounts, highlighting 25 controls designed to mitigate the risk of errors in discount distributions. However, recommendations were made to improve resolution processes for non-payment issues, emphasizing the need for better communication channels with manufacturers.
Meanwhile, FTI Consulting’s findings showed that UnitedHealth performed relatively well compared to its competitors in relation to Medicaid and Medicare, although they raised concerns regarding slow decision-making processes and documentation practices. The firm highlighted the need for UnitedHealth to better address issues flagged during regulatory audits.
In addition to these findings, UnitedHealth promised to share further results from an extensive review of medical records and plans to outline its evidence-based medical policy by mid-year. This comes at a time when UnitedHealth’s shares have plummeted over 35% this year, a decline linked to rising medical costs, the abrupt change in leadership, and ongoing investigations into its Medicare Advantage segment. The backdrop of this restructuring is also overshadowed by the historic cyberattack the company faced in 2014, as well as public scrutiny following the high-profile murder of its former CEO, Brian Thompson.
